Male C57BL/6 wild‐type mice were purchased from the Laboratory Animal Center of Southern Medical University. C57BL/6 Gsdme‐knockout (Gsdme−/−) mice were generated by CRISPR/Cas‐mediated genome engineering (Cyagen Bioscience). CIA was induced in 8‐week‐old male wild‐type and Gsdme−/− mice. Chicken type II collagen (catalog no. 20012; Chondrex) was dissolved in 0.05M acetic acid (final concentration 2 mg/ml) and then emulsified with Freund's complete adjuvant (CFA) containing heat‐killed Mycobacterium tuberculosis H37RA (Chondrex). C57BL/6 mice were injected intradermally with a 100‐μl emulsion at the base of tail on days 1 and 21 (33 (link)). Clinical assessment of CIA was performed daily for each limb as previously described (34 (link)).
CIA was generated in DBA/1J mice as previously described (35 (link)). Eight‐week‐old male DBA/1J mice were immunized with 100 mg bovine type II collagen (2 mg/ml; Chondrex) emulsified 1:1 in CFA (containing 1 mg/ml M tuberculosis; Chondrex) on day 1 and then injected with Freund's incomplete adjuvant (Chondrex) on day 21.
All animals were maintained under specific pathogen–free conditions in the Laboratory Animal Center of Southern Medical University. The protocols for animal experimentation were approved by the Southern Medical University Experimental Animal Ethics Committee (no. 00171035 and no. 00181785).
CIA was generated in DBA/1J mice as previously described (35 (link)). Eight‐week‐old male DBA/1J mice were immunized with 100 mg bovine type II collagen (2 mg/ml; Chondrex) emulsified 1:1 in CFA (containing 1 mg/ml M tuberculosis; Chondrex) on day 1 and then injected with Freund's incomplete adjuvant (Chondrex) on day 21.
All animals were maintained under specific pathogen–free conditions in the Laboratory Animal Center of Southern Medical University. The protocols for animal experimentation were approved by the Southern Medical University Experimental Animal Ethics Committee (no. 00171035 and no. 00181785).
